角膜交联对比标准护理对年轻圆锥角膜患者进展的影响:KERALINK随机对照试验
KERALINK随机对照试验纳入60例10至16岁进展性圆锥角膜患者,比较角膜交联联合标准护理与单纯标准护理。18个月时交联组平均陡峭K2为49.7 D,标准护理组为53.4 D,校正均差-3.0 D(95%CI -4.9至-1.1 D;P=0.002),支持交联。交联组进展2例(7%),标准护理组12例(43%)。结论认为交联可阻止多数年轻患者圆锥角膜进展,可考虑作为进展性疾病的一线治疗。
要点
- 年轻进展性圆锥角膜患者中,角膜交联18个月时K2较标准护理显著更低。
- 交联组圆锥角膜进展发生率低于标准护理组(7% vs 43%)。
- 交联组未校正与校正视力调整后差异均支持交联。
核心结论
- 角膜交联可阻止多数年轻圆锥角膜患者的疾病进展。
- 进展性圆锥角膜应将角膜交联考虑为一线治疗。
- 若交联阻止进展的效果在更长随访中持续,可能特别有助于避免后期需要配戴接触镜或角膜移植。
研究设计与样本
- 观察者设盲、随机、对照、平行组优效性试验。
- 纳入60例10至16岁进展性圆锥角膜患者,每例选取一只眼作为研究眼。
- 研究眼随机分配至角膜交联联合标准护理组或单纯标准护理组,必要时使用框架眼镜或接触镜矫正视力。
- 主要结局为随机化后18个月研究眼陡峭角膜曲率(K2)。
主要发现
- 随机化后18个月研究眼平均K2在交联组为49.7 D(标准差3.8 D),标准护理组为53.4 D(标准差5.8 D)。
- 研究眼K2校正均差为-3.0 D(95%CI -4.9至-1.1 D;P=0.002),支持交联组。
- 未校正视力组间校正差异为-0.31 logMAR(95%CI -0.50至-0.11 logMAR;P=0.002),支持交联组。
- 校正视力组间校正差异为-0.51 logMAR(95%CI -1.37至0.35 logMAR;P=0.002),支持交联组。
- 研究眼圆锥角膜进展在交联组为2例(7%),标准护理组为12例(43%);未校正比值比0.1(95%CI 0.02-0.48;P=0.004)。
关键数值与推荐
- 圆锥角膜进展定义为K2增加1.5 D。
- 60例参与者中,交联组30例和标准护理组30例被随机分配;交联组30例和标准护理组28例纳入分析。
临床怎么用
- 对年轻进展性圆锥角膜患者,角膜交联可作为一线治疗选择以阻止进展。
- 评估疗效时可关注18个月时陡峭K2变化及圆锥角膜进展(K2增加1.5 D)情况。
局限性
- 原文未报告随访超过18个月的数据。
- 原文未报告除视力、角膜厚度和生活质量以外的其他次要结局具体结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine the efficacy and safety of corneal cross-linking (CXL) for stabilization of progressive keratoconus. DESIGN: Observer-masked, randomized, controlled, parallel-group superiority trial. PARTICIPANTS: Sixty participants 10 to 16 years of age with progressive keratoconus, one eye of each deemed the study eye. METHODS: The study eye was randomized to either CXL plus standard care or standard care alone, with spectacle or contact lens correction as necessary for vision. MAIN OUTCOME MEASURES: The primary outcome was steep keratometry (K2) in the study eye as a measure of the steepness of the cornea at 18 months. Secondary outcomes included keratoconus progression defined as a 1.5-diopter (D) increase in K2, visual acuity, keratoconus apex corneal thickness, and quality of life. RESULTS: Of 60 participants, 30 were randomized to CXL and standard care groups. Of these, 30 patients in the CXL group and 28 patients in the standard care group were analyzed. Mean K2 in the study eye 18 months after randomization was 49.7 D (standard deviation [SD], 3.8 D) in the CXL group and 53.4 D (SD, 5.8 D) in the standard care group. The adjusted mean difference in K2 in the study eye was -3.0 D (95% confidence interval [CI], -4.9 to -1.1 D; P = 0.002), favoring CXL. Adjusted differences between groups in uncorrected and corrected vision favored eyes receiving CXL: -0.31 logarithm of the minimum angle of resolution (logMAR; 95% CI, -0.50 to -0.11 logMAR; P = 0.002) and -0.51 logMAR (95% CI, -1.37 to 0.35 logMAR; P = 0.002). Keratoconus progression in the study eye occurred in 2 patients (7%) randomized to CXL compared with 12 patients (43%) randomized to standard care. The unadjusted odds ratio suggests that on average, patients in the CXL arm had 90% (odds ratio, 0.1; 95% CI, 0.02-0.48; P = 0.004) lower odds of experiencing progression compared with those receiving standard care. CONCLUSIONS: CXL arrests progression of keratoconus in the majority of young patients. CXL should be considered as a first-line treatment in progressive disease. If the arrest of keratoconus progression induced by CXL is sustained in longer follow-up, particular benefit may be derived from avoiding a later requirement for contact lens wear or corneal transplantation.
引用
- Larkin DFP, Chowdhury K, Burr JM, et al. Effect of Corneal Cross-linking versus Standard Care on Keratoconus Progression in Young Patients: The KERALINK Randomized Controlled Trial. Ophthalmology. 2021. PMID: 33892046. doi:10.1016/j.ophtha.2021.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。